Navigation Links
Monoclonal Antibody Partnering Terms & Agreements Discussed in New Report Now Available at MarketPublishers.com
Date:12/12/2012

London, UK (PRWEB) December 12, 2012

Monoclonal antibodies (mAb) represent one of the fastest growing segments of the global pharmaceutical market. In 2010, mAb market revenues amounted to more than USD 42.5 billion. Amgen Inc, Johnson & Johnson, Novartis AG, Eli Lilly and Company Biogen Idec, Merck & Co Inc, Abbott Laboratories and Roche Holding Ltd. are amid leading companies on the mAb market. The U.S. and Japan are the most prominent country markets for mAb.

New research report “Monoclonal Antibody Partnering Terms and Agreements” elaborated by CurrentPartnering has been recently published by Market Publishers Ltd.

Report Details:

Title: Monoclonal Antibody Partnering Terms and Agreements
Published: December, 2012
Pages: 1252
Price:    US$ 2,695.00
http://marketpublishers.com/report/life_sciences/biotechnology/monoclonal-antibody-partnering-terms-n-agreements.html

The report delves into the monoclonal antibody market and reviews partnering deals and agreements in 2007-2012. The research study provides an extensive analysis of the mAb dealmaking directory by deal type, stage of development and by therapy indicators. Besides, the report thoroughly examines monoclonal antibody deals by technology type. The report offers comprehensive assessment of partnering deals and points out key market trends. It also indicates top companies active in the market and includes bigpharma monoclonal antibody partnering company profiles. Moreover, the research contains contract documents, deals’ records and their financial terms.

Reasons to Buy:

  •     The report offers a detailed overview of the global monoclonal antibodies market.
  •     The research study provides an in-depth understanding of trends of the monoclonal antibody market. It also unveils valuable data on partnering in the research, development and commercialization of biomarker technologies and products.
  •     The extensive analysis of the changing nature of deals terms provides an insight into the negotiation process and shows what one can expect to achieve during the negotiation of terms.
  •     The reports will help you to find answers to numerous questions about a prospective partner’s flexibility on a raft of important issues

More new market research reports and databases by the publisher can be found at CurrentPartnering page.

Read the full story at http://www.prweb.com/releases/2012/12/prweb10230559.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
2. GeneTex Launches New Antibody Against Phosphorylated Histone H3 for Epigenetics Research
3. NKT Therapeutics Presents Data on Potential Antibody Treatment for Sickle Cell Disease
4. Ebola antibody treatment, produced in plants, protects monkeys from lethal disease
5. Preclinical data shows 100 percent prevention and treatment of influenza with engineered human antibody
6. Oncobiologics, Inc. Announces a Collaboration Agreement with XOMA Corporation to Utilize XOMAs Fully Human Antibody Libraries for Their Discovery Platform
7. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
8. RayBiotech, Inc. and the University of Oslo Enter into Antibody Array Services Collaboration
9. Sinovac to Present at 55th Annual BioPharma China Convention 2012 - Vaccine & Antibody Focus
10. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
11. AnaptysBio Announces Antibody Discovery Partnership With Gilead Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
(Date:6/23/2016)... India , June 23, 2016 ... media market research report to its pharmaceuticals section ... profiles, product details and much more. ... spread across 151 pages, profiling 15 companies and ... available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
Breaking Biology Technology:
(Date:6/27/2016)... June 27, 2016 Research and Markets has ... 2016-2020" report to their offering. ... America to grow at a CAGR of 12.28% during ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:6/22/2016)... , June 22, 2016  The American College of Medical ... Show Executive Magazine as one of the fastest-growing trade ... 25-27 at the Bellagio in Las Vegas ... highest percentage of growth in each of the following categories: ... companies and number of attendees. The 2015 ACMG Annual Meeting ...
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
Breaking Biology News(10 mins):